As of Sept. 22, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
Here’s the latest list of major overbought players in this sector.
Thermo Fisher Scientific Inc (NYSE:TMO)
- CLSA analyst Michael Luo, on Sept. 3, initiated coverage on Thermo Fisher Scientific with an Outperform rating and announced a price target of $748. The company’s stock gained around 7% over the past five days and has a 52-week high of $663.57.
- RSI Value: 71.7
- TMO Price Action: Shares of Thermo Fisher Scientific gained 1.2% to close at $658.76 on Monday.
- Edge Stock Ratings: 91.72 Momentum score with Value at 16.50.
Moderna Inc (NASDAQ:MRNA)
- On Sept. 21, the company announced three abstracts on its mRNA-based individualized neoantigen therapy intismeran autogene have been accepted for presentation at the ESMO Congress 2026. The company’s stock gained around 25% over the past month and has a 52-week high of $176.86.
- RSI Value: 74.3
- MRNA Price Action: Shares of Moderna jumped 12.3% to close at $172.94 on Monday.
Agilent Technologies Inc (NYSE:A)
- On Sept. 16, Agilent announced a cash dividend of 25.5 cents per share. The company’s stock gained around 10% over the past five days and has a 52-week high of $163.75.
- RSI Value: 73.7
- A Price Action: Shares of Agilent rose 3.5% to close at $161.94 on Monday.
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.
Photo via Shutterstock
Login to comment